ICER views Pierre Fabre’s tab-cel for Epstein-Barr virus

US health technology assessor the Institute for Clinical and Economic Review (ICER) as  released a Final Evidence Report assessing the comparative clinical effectiveness of French drugmaker Pierre Fabre’s tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

EBV+ PTLD is a rare and often fatal cancer associated with solid organ transplant and stem cell transplant,” said ICER’s vice president of research Foluso, adding: “Unfortunately, approximately half of EBV+ PTLD cases do not respond to initial treatment or relapse, resulting in a poor prognosis. The limited evidence on tabelecleucel suggests that it provides important clinical benefits in patients with relapsed refractory EBV+ PTLD, extending survival for patients who otherwise do not usually survive beyond a few weeks to months, with few harms.”

The ICER assessed, and the independent appraisal committee voted on the evidence for people with relapsed/refractory EBV+ PTLD, who have received at least one prior therapy: